中文产业新闻评分61Chinese source
admilparant 60 mg 达主要终点，120 mg 组未显著且 BMS 股价转跌
安全性无虞，LPA1高剂量疗效不显著，BMS转跌
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.
安全性无虞，LPA1高剂量疗效不显著，BMS转跌
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.